Post-Traumatic Stress Disorder (PTSD) Research
The Mood and Anxiety Disorders Program (MAP) is researching a range of new treatments for post-traumatic stress disorder (PTSD). Our studies include research into finding novel uses for current medications such as ketamine (an FDA-approved anesthetic) and developing new drugs.
Clinical Trials for Post-Traumatic Stress Disorder (PTSD)
MAP is currently seeking individuals interested in participating in the following clinical trials for PTSD.
- An inhibitor of the “stress hormone” (corticotropin releasing factor antagonist) for the Treatment of PTSD: Investigates the efficacy of using a corticotropin releasing factor antagonist to inhibit the release of stress hormones in patients with PTSD.
- Intranasal Administration of Neuropeptide Y in PTSD: Studies the antidepressant and anti-anxiety effect of intranasal administration of neuropeptide Y (NPY) for patients with post-traumatic stress disorder (PTSD).
- Cognitive Training for Mood and Anxiety Disorders: Investigates the effectiveness of a computerized training program to help depressed and anxious individuals modify the negative bias with which they perceive and process information.
To participate in one of our clinical trials for Mood and Anxiety Disorders or to learn more about eligibility, please contact us (212-241-6539; firstname.lastname@example.org).